Thoracic Malignancies

Myeloproliferative Neoplasms

Questions discussed in this category

How would you approach giving concurrent chemoradiation for Stage IIIB lung adenocarcinoma in the setting of concurrent Int-2 myelofibrosis which has been stable without cytopenias on ruxolitinib?

Would you modify the radiation dose or field in this setting? Would you pre-emptively dose reduce chemotherapy, or modify the dosing of ruxolitinib?

1 Answer available

Related Topics in Thoracic Malignancies